Comparison of rabbit ATLG and ATG for GVHD prophylaxis in hematological malignancies with haploidentical hematopoietic stem cell transplantation
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
Rabbit anti-human T lymphocyte globulin (ATLG) and anti-thymocyte globulin (ATG) are commonly used for graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (HSCT). Yet, their efficacy and safety have seldom been compared in hematological malignancies with haploidentical HSCT. A retrospective analysis with 28 ATLG (total dosage, 20-30 mg/kg) and 18 ATG (total dosage, 8-10 mg/kg) patients were performed. The cumulative incidences of chronic GVHD and relapse were comparable between both groups. ATLG showed a trend towards a lower acute GVHD incidence (28.6% vs. 44.4%, P = 0.242) and 3-year non-relapse mortality (10.7% vs. 27.8%, P = 0.160), and had a significantly higher 3-year overall survival (OS, 64.3% vs. 33.3%, P = 0.033) and GVHD-free and relapse-free survival (GRFS, 32.1% vs. 11.1%, P = 0.045) compared with ATG. Multivariate Cox regression analysis demonstrated ATLG was independently associated with a favorable OS (hazard ratio [HR] = 0.37, 95% confidence interval [CI]: 0.16-0.86, P = 0.020) and GRFS (HR = 0.51, 95%CI: 0.26-1.00, P = 0.051). Furthermore, ATLG had a lower risk of fever (25.0% vs. 61.1%, P = 0.014) and hemorrhage cystitis (7.1% vs. 38.9%, P = 0.008) than ATG-T. In conclusion, ATLG confers more survival benefit and a better safety profile than ATG and can be used in hematological malignancies with haploidentical HSCT. Prospective designed trials with a larger sample size are warranted to confirm the results in the future.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
---|---|
Enthalten in: |
Annals of hematology - 103(2024), 5 vom: 28. Apr., Seite 1729-1736 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tian, Zhengqin [VerfasserIn] |
---|
Links: |
---|
Themen: |
Anti-human T lymphocyte globulin |
---|
Anmerkungen: |
Date Completed 15.04.2024 Date Revised 15.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s00277-024-05724-w |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370285212 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM370285212 | ||
003 | DE-627 | ||
005 | 20240415233555.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240329s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00277-024-05724-w |2 doi | |
028 | 5 | 2 | |a pubmed24n1376.xml |
035 | |a (DE-627)NLM370285212 | ||
035 | |a (NLM)38538977 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Tian, Zhengqin |e verfasserin |4 aut | |
245 | 1 | 0 | |a Comparison of rabbit ATLG and ATG for GVHD prophylaxis in hematological malignancies with haploidentical hematopoietic stem cell transplantation |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 15.04.2024 | ||
500 | |a Date Revised 15.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
520 | |a Rabbit anti-human T lymphocyte globulin (ATLG) and anti-thymocyte globulin (ATG) are commonly used for graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (HSCT). Yet, their efficacy and safety have seldom been compared in hematological malignancies with haploidentical HSCT. A retrospective analysis with 28 ATLG (total dosage, 20-30 mg/kg) and 18 ATG (total dosage, 8-10 mg/kg) patients were performed. The cumulative incidences of chronic GVHD and relapse were comparable between both groups. ATLG showed a trend towards a lower acute GVHD incidence (28.6% vs. 44.4%, P = 0.242) and 3-year non-relapse mortality (10.7% vs. 27.8%, P = 0.160), and had a significantly higher 3-year overall survival (OS, 64.3% vs. 33.3%, P = 0.033) and GVHD-free and relapse-free survival (GRFS, 32.1% vs. 11.1%, P = 0.045) compared with ATG. Multivariate Cox regression analysis demonstrated ATLG was independently associated with a favorable OS (hazard ratio [HR] = 0.37, 95% confidence interval [CI]: 0.16-0.86, P = 0.020) and GRFS (HR = 0.51, 95%CI: 0.26-1.00, P = 0.051). Furthermore, ATLG had a lower risk of fever (25.0% vs. 61.1%, P = 0.014) and hemorrhage cystitis (7.1% vs. 38.9%, P = 0.008) than ATG-T. In conclusion, ATLG confers more survival benefit and a better safety profile than ATG and can be used in hematological malignancies with haploidentical HSCT. Prospective designed trials with a larger sample size are warranted to confirm the results in the future | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Anti-human T lymphocyte globulin | |
650 | 4 | |a Graft-versus-host disease | |
650 | 4 | |a Haploidentical hematopoietic stem cell transplantation | |
650 | 4 | |a Hematological malignancy | |
650 | 4 | |a Overall survival | |
650 | 7 | |a Antilymphocyte Serum |2 NLM | |
700 | 1 | |a Man, Qihang |e verfasserin |4 aut | |
700 | 1 | |a Yang, Yixin |e verfasserin |4 aut | |
700 | 1 | |a Guan, Hexian |e verfasserin |4 aut | |
700 | 1 | |a Wang, Ying |e verfasserin |4 aut | |
700 | 1 | |a Luo, Rongmu |e verfasserin |4 aut | |
700 | 1 | |a Wang, Jingbo |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d 1991 |g 103(2024), 5 vom: 28. Apr., Seite 1729-1736 |w (DE-627)NLM012918768 |x 1432-0584 |7 nnns |
773 | 1 | 8 | |g volume:103 |g year:2024 |g number:5 |g day:28 |g month:04 |g pages:1729-1736 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00277-024-05724-w |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 103 |j 2024 |e 5 |b 28 |c 04 |h 1729-1736 |